Abdul Rafeh Naqash, MD, advanced fellow, Early Clinical Trials Development Program, National Cancer Institute, discusses the results of a tumor profiling study in 

 co-mutated non–small cell lung cancer (NSCLC). 

, findings from an analysis were presented that demonstrated that patients with NSCLC who harbor 

 co-mutations have more immunologically active tumor microenvironments with metabolic reprogramming compared with 

Of 16,896 NSCLC samples, 12.6% of patients harbored an 

 mutations had the proportions of tumor mutation burden (TMB)–high (10 or more mutations per megabase) disease, 11.8% were PD-L1 positive (50% or greater by 22C3 antibody testing), and 0.72% were microsatellite instability high, Naqash explains. 

No differences were observed comparing TMB between the 

 led to higher median TMB and neoantigen load compared with 

Videos

Abdul Rafeh Naqash, MD, discusses the results of a tumor profiling study in STK11 and TP53 co-mutated non–small cell lung cancer. 



Dr. Naqash on the Results of a Tumor Profiling Study in STK11/TP53 Co-Mutated NSCLC 

Abdul Rafeh Naqash, MD, an advanced fellow in the Early Clinical Trials Development Program and the Developmental Therapeutics Clinic at the National Cancer Institute, and Alice Chen, MD, head of the Early Clinical Trials Development Program and Developmental Therapeutics Clinic, at the National Cancer Institute, discuss the phase 2 trial evaluating the efficacy of atezolizumab (Tecentriq) in patients with advanced alveolar soft part sarcoma.

As of April 2021, 46 of 53 patients have been enrolled on a phase 2 trial (NCT03141684) studying the agent, 45 of whom have already received treatment, according to Naqash. Investigators reported an objective response rate of 37.2%, with a median duration of confirmed response of 16.6 months, and a median time to confirmed response of 3.5 months.

Interestingly, 3 patients who had been on a treatment holiday as per protocol had maintained their partial responses for a median duration of 8.6 months. These evaluations suggest that atezolizumab has promising clinical activity in patients with alveolar soft part sarcoma, Naqash says.

Future direction will focus on the addition of bevacizumab (Avastin) as an anti-angiogenesis agent in patients who have progressed on atezolizumab, according to Chen. Additionally, previous reports have indicated that a combination of pembrolizumab (Keytruda) and axitinib (Inlyta) have demonstrated promising activity in this patient population. Moreover, bevacizumab and atezolizumab have been examined in other histologies, such as hepatocellular carcinoma, with positive results, Chen says.

The combination is currently being examined in patients with alveolar soft part sarcoma in order to overcome resistance to atezolizumab, as the anti-angiogenesis component of bevacizumab could change the microenvironment and immunotherapy effect, Chen concludes.

Abdul Rafeh Naqash, MD, and Alice Chen, MD, discuss their phase 2 trial evaluating the efficacy of atezolizumab in patients with advanced alveolar soft part sarcoma.

Abdul Rafeh Naqash, MD

Articles

Dr. Naqash on the Results of a Tumor Profiling Study in STK11/TP53 Co-Mutated NSCLC

Dr. Naqash and Dr. Chen on the Efficacy of Atezolizumab in Advanced Alveolar Soft Part Sarcoma